Literature DB >> 34961659

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

M T Corkum1, V Achard2, G Morton3, T Zilli4.   

Abstract

Following adoption of moderately hypofractionated radiotherapy as a standard for localised prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is rapidly being embraced by clinical practice and international guidelines. However, the question remains: how low can we go? Can radiotherapy for prostate cancer be delivered in fewer than five fractions? The current review summarises the evidence that radiotherapy for localised prostate cancer can be safely and effectively delivered in fewer than five fractions using high dose rate brachytherapy or stereotactic body radiotherapy. We also discuss important lessons learned from the single-fraction high dose rate brachytherapy experience.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Dose fractionation; high dose rate brachytherapy; prostate cancer; stereotactic body radiotherapy

Mesh:

Year:  2021        PMID: 34961659     DOI: 10.1016/j.clon.2021.12.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  When Less is More: The Rising Tide of Hypofractionation.

Authors:  K Aitken; S Mukherjee
Journal:  Clin Oncol (R Coll Radiol)       Date:  2022-03-16       Impact factor: 4.925

2.  Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer.

Authors:  Jose Luis Guinot; Juan Casanova; Victor Gonzalez-Perez; Miguel Angel Santos; Victor De Los Dolores; Maria Isabel Tortajada; Carmen Guardino; Vicente Crispin; Jose Rubio-Briones; Leoncio Arribas
Journal:  J Contemp Brachytherapy       Date:  2022-05-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.